At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 44 enrolled
Drug / intervention
2% dorzolamidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration
In Brief
A Phase 4 clinical trial evaluating 2% dorzolamide for Retinal Degenerations. Completed, enrolled 44 participants across 1 site.
Detailed Summary
A small percentage of patients with retinal degeneration accumulate fluid in the center of their retina. Previous studies using an oral form of treatment has been successful in decreasing this fluid which improves vision. This study will test the use of a topically applied form of this treatment to the eye to reduce the amount of fluid and improve or preserve vision.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinal Degenerations
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
First PostedJul 2008
Primary CompletionAug 2015
Study CompletionNov 2017
TodayJul 2026
First PostedJul 16, 2008
Enrollment StartOct 1, 2005
Primary CompletionAug 11, 2015
Study CompletionNov 17, 2017
TodayJul 2, 2026
Enrollment to primary: 9.9 yearsPosted 18.0 years ago
Interventions
2% dorzolamidedrug
Carbonic anhydrase inhibitor, Trusopt (2% dorzolamide)